In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuvelo Inc.

Division of ARCA biopharma Inc.
www.nuvelo.com

Latest From Nuvelo Inc.

Amazon Versus Biotech: How The IPO Class Of '97 Worked Out

Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.

Financing Growth

Where Are They Now? Checking In On Four Cardiovascular Start-Ups

It's no secret increasing generic competition and regulatory oversight, combined with the financial challenges of developing a primary care drug, make cardiovascular a tough place for venture-backed biotechs. START-UP takes the pulse of four previously profiled cardiovascular companies -- arca Biopharma, Celladon, NovaCardia and Portola Pharmaceuticals, -- to see what lessons they've learned.
BioPharmaceutical Strategy

New appointments at Onyx Pharmaceuticals

Onyx Pharmaceuticals (US) has appointed Dr Ted Love executive vice-president and head of R&D. Dr Michael Kauffman, who has been interim chief medical officer since November 2009, becomes chief medical officer, reporting to Dr Love. Most recently, Dr Love served as president, CEO and chairman at the biotechnology company Nuvelo. Before that, he was senior vice-president of development at Theravance.

Companies

Reacting to the Crisis: Biotech Venture Capital's Plan B

There are significant dilemmas facing life sciences venture capitalists buffeted by the simultaneous but distinct insults of global financial calamity and trickier-than-ever biotech partnering, regulatory, and reimbursement environments. Venture's best bet at a return is an uptick in decidedly un-venture PIPE deals that take advantage of public biotechs' miserable valuations, but those deals aren't exactly growing on trees. Despite the surfeit of bad news, there may be a bright side.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Variagenics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ARCA biopharma Inc.
  • Senior Management
  • Lee Bendekgey, SVP, CFO
    Simon Allen, VP, Corp. & Bus. Dev.
    Michael Levy, MD, SVP, R&D
  • Contact Info
  • Nuvelo Inc.
    Phone: (650) 517-8000
    201 Industrial Road, Suite 310
    San Carlos, CA 94070-6211
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register